Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil by Teixeira, Alan César et al.
Rev. Inst. Med. trop. S. Paulo
50(3):157-160, May-June, 2008
(1) Curso de Pos-graduação em Medicina Tropical e Infectologia, Universidade Federal do Triângulo Mineiro, Caixa postal 118, 38001-970 Uberaba, MG, Brazil.
(2) Fundação de Medicina Tropical do Amazonas, Avenida Pedro Teixeira 25, 69040-000 Manaus, AM, Brazil.
Correspondence to: Prof Mario León Silva-Vergara, Medicina Tropical/UFTM, Caixa Postal 118, 38001-970 Uberaba, MG, Brasil. Tel.: +55 34 3318 5286, Fax: +55 34 3318 5279.
E-mail: marioleon.dip@mednet.com.br (M.L. Silva-Vergara).
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LEISHMANIASIS IN MANAUS, AM, BRAZIL
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SUMMARY
A non-randomized controlled clinical trial was carried out in order to evaluate both azithromycin and antimony efficacy in
cutaneous leishmaniasis in Manaus, AM, Brazil. Forty nine patients from both genders, aged 14 to 70, with cutaneous ulcers for
less than three months and a positive imprint for Leishmania spp. amastigotes were recruited into two groups. Group I (26
patients) received a daily-single oral dose of 500 mg of azithromycin for 20 days and Group II (23 patients) received a daily-single
intramuscular dose of 20 mg/kg of meglumine antimony, also for 20 days. Azithromycin cured three of 24 (12.5%) patients on
days 60, 90 and 120 respectively whereas therapeutic failure was considered in 21 of 24 (87.5%) cases. In group II, antimony cured
eight of 19 (42.1%) cases as follows: three on day 30, one each on day 60 and day 90, and three on day 120. Therapeutic failure
occurred in 11 of 19 (57.9%) individuals. The efficacy of antimony for leishmaniasis was better than azithromycin but analysis for
the intention-to-treat response rate did not show statistical difference between them. Although azithromycin was better tolerated,
it showed a very low efficacy to treat cutaneous leishmaniasis in Manaus.
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INTRODUCTION
Leishmaniasis has been treated for decades with pentavalent
antimony, pentamidine or amphotericin B but patients cure rate presents
high variability depending on Leishmania spp., clinical picture and
geographical location (SARAVIA et al, 1989; ROMERO et al., 2001).
Several studies have evaluated oral medicaments to treat cutaneous
leishmaniasis caused by different Leishmania spp. without conclusive
results (DOGRA & SAXENA, 1996; ALRAJHI et al., 2002). Recently,
patients with cutaneous leishmaniasis caused by L. (Viannia)
panamensis in Colombia received miltefosine and presented cure rate
of 91%, whereas, in Guatemala, only 50% of cure was obtained in
patients infected by L. (Viannia) brasiliensis (SOTO et al., 2004). The
results in patients with visceral leishmaniasis in India also showed
good efficacy (93%) with this drug (SUNDAR et al., 2002).
Azithromycin has been used to treat infections caused mainly by
intracellular microorganisms because of its tissular distribution within
phagocytes and its long half life (PETERS et al., 1992; WILDFEUER
et al., 1996). This drug has shown activity against Toxoplasma gondii,
Plasmodium vivax and Cryptosporidium spp., among others
(GIACOMETTI et al., 2000; PUKRITTAYAKAMEE et al., 2003).
In an experiment in-vitro and in-vivo model, azithromycin showed
activity against Leishmania major (KROLEWIECKI et al., 2002). In
an open trial in Brazil, it cured 16 out of 20 patients with cutaneous
ulcers caused by Leishmania (Viannia) braziliensis, however, cure time,
doses and cycles number presented high variability (PRATA et al.,
2003). In the same location; three out of four old individuals with
mucosal involvement presented clinical cure after several cycles with
this drug (SILVA-VERGARA et al., 2004). Most recently, in an open
study, none of 45 Syrian old-world leishmaniasis patients treated with
azithromycin were cured (DAOUD & BOUSHI, 2006). The aim of
this trial was to compare both azithromycin and antimony efficacy in
patients with cutaneous leishmaniasis.
PATIENTS AND METHODS
This trial was carried out in an endemic leishmaniasis area where
high active transmission occurs due to deep ecosystem changes
introduced in the last decades to enlarge agriculture borders, settlements
alongside the roads and non-planned urbanization replacing native
jungle. The patients recruited were referred by other clinicians selected
among several hundred of local residents that were diagnosed during
2003 at the Fundação de Medicina Tropical do Amazonas, a
leishmaniasis state reference center.
Sample size was estimated in 202 cases with Yates correction
considering 30% and 50% of cure to antimony and azithromycin
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respectively. Criteria for enrollment were as follows: individuals of
both genders, aged 14 to 70, presenting cutaneous ulcers for less than
12 weeks and a positive imprint for Leishmania spp. amastigotes.
Exclusion criteria: patients with history of treatment for leishmaniasis
in the last three months, difficulty to attend follow-up, mucosal or
diffuse involvement, fever, previous macrolide or antimony allergy,
pregnancy, diabetes mellitus, AIDS, vasculitis, use of corticosteroids
or immunosuppressive drugs, renal, hepatic or cardiac diseases and/or
engaged in another clinical trial.
 The consent to enrollment was obtained prior to allocation. The
patients were clinically examined and number, diameter and size of
lesions were assessed. A intradermal test using standard antigen was
performed in all according to procedure already described (MAYRINK
et al., 1979).
Patients were allocated in two groups according to individual choice
of treatment. Group I received a daily-single oral dose of 500 mg of
azithromycin for 20 days and Group II received a daily-single
intramuscular dose of 20 mg/kg of meglumine antimony during the
same period under supervision. Clinical follow-up was carried out every
30 days and all complaints, compliance and secondary effects were
evaluated by spontaneous report and questionnaire.
 Cure criteria were characterized by the whole epithelization of
skin ulcers and the absence of erythema and/or inflammatory signs.
Therapeutic failure was defined if lesions worsened on days 30, 60, 90
or 120 of follow-up despite an early good response.
Data analysis was performed using statistical for windows, 6.0
(Statsoft, Inc. USA). Shapiro-wilk test for normal distribution and
Student’s t test for independent samples, Mann-Withney for abnormal
distributions and χ2 tests for comparing proportions. The project was
approved by the ethical review board from Fundação de Medicina
Tropical do Amazonas, Manaus, AM, Brazil.
RESULTS
From January to April 2003, forty nine patients with cutaneous
leishmaniasis were recruited. Most of them were males under 35 years
old. From these, 26 (53%) received azithromycin (Group I) and 23
(47%) received antimony (Group II). The main demographic and
clinical characteristics of both groups were similar (Table 1).
Clinical cure was noticed in three of 24 (12.5%) cases of Group I
on days 60, 90 and 120 respectively, whereas, 21 of 24 (87.5%) patients
presented therapeutic failure as follows: on day 30 of treatment, 19
worsened and two had improved but worsened on day 60, then, they
were all switched to antimony.
From Group II, eight of 19 (42.5%) cases were cured as follows:
three on day 30, one each on day 60 and day 90, and three on day 120.
The remaining 11 of 19 (57.9%) improved on day 30, but seven of
them worsened on day 60 and four on day 90 and then received another
20-day cycle of antimony. Two patients of the azithromycin group and
four of the antimony group did not attend follow-up (Table 2).
In general, azithromycin was well tolerated, however, diarrhea,
abdominal pain, dizziness, headache and nausea were reported by 60%,
28%, 24%, 12% and 12% of them respectively but no patient interrupted
the therapy because of these side effects On the other hand, patients
receiving antimony, often complained of arthralgia and myalgia and
Table 1
Epidemiological and clinical characteristics of 49 patients with cutaneous
leishmaniasis in Manaus, AM, Brazil
Characteristics Group I Group II p value
N % N %
Age(years)
14-34 16 61.5 16 69.5 0.54
35-49 10 38.5 7 30.5
Gender
Male 21 80.8 21 91.3 0.20
Female 5 19.2 2 7.7
Skin lesions(weeks)
< 4 21 80.8 19 82.6 0.59
5-8 4 15.4 4 17.4
Multiple ulcers 17 65.4 13 56.5 0.14
Classical ulcer 18 69.3 12 52.1
Supraumbilical lesions 13 50.0 11 47.8 0.45
Ulcers with bacterial 15 57.7 7 30.4 0.05
infection
Ulcer diameter < 2 cm 18 69.0 17 74.0 0.80
Positive intradermal test 21 84.0 20 91.0 0.43
Table 2
Azithromycin efficacy in 49 patients with cutaneous leishmaniasis in Manaus, AM, Brazil
Follow-up/day 0 30 60 90 120
I II I II I II I II I II
Allocation 26 23 - - - - - - - -
Improving - - 5 16 2 4 1 - - -
Clinical cure - - - 3 1 1 1 1 1 3
Worsening - - 19* - 2* 7** - 4** - -
Lost to follow-up - - 2 4 - - - - - -
Group I: Azithromycin - Group II: Antimony; *: switched to Antimony; **: new treatment with Antimony.
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only four withdrew it due to the severity of these symptoms but their
lesions cured.
Overall, azithromycin cured three of 24 (12.5%) patients and
antimony eight of 19 (42.5%) (χ2 5.22, p = 0.035, OR = 5.33 and IC
95% 0.98-32.3). The analysis for the intention-to-treat response rate
did not show statistical difference between the two groups.
DISCUSSION
Due to limited evidence about azithromycin activity against
Leishmania spp., this trial compared it with antimony in 49 patients
with cutaneous leishmaniasis from an area where L. (Viannia)
guyanensis causes 97% of infections (LAINSON & SHAW, 1987;
GRIMALDI et al., 1989).
Azithromycin cured only three of 24 (12.5%) cases, similar to the
results obtained in a pilot study in the same place (TEIXEIRA et al.,
2007). In contrast, an open non-controlled study carried out in an
endemic area where L. (Viannia) braziliensis prevails, azithromycin
cured 16 of 20 (85%) patients with cutaneous ulcers although the doses,
treatment and cure time were variable (PRATA et al., 2003).
Spontaneous cure in leishmaniasis often occurs after six months
and it was unlikely to have occurred in the three patients cured as the
epithelization of their lesions began with azithromycin administration
and were wholly cured up to four months, which suggests some drug
effect and not spontaneous healing only. Besides, one of the inclusion
criteria was ulcer with less than 12 weeks.
It has been suggested that early treatment of patients with
leishmaniasis can not represent an advantage at least during the first
four weeks when compared with the results observed in patients with
long term lesions. Most individuals in this trial presented ulcers with
less than four weeks which could have contributed to the poor outcome
observed (ROCHA et al., 1999).
The proportion of patients that presented ulcers with evidence of
bacterial infection was significantly higher in the azithromycin group
(57.7% vs 30.4%) but, no difference related to response was observed
between them. That may be explained by the selection bias during
allocation. Besides, a former report has shown that bacterial secondary
infection did not influence the healing process in cutaneous
leishmaniasis (VERA et al., 2001).
The prolonged half life (2-6 days) and high intra-phagocyte
concentration of azithromycin together with good tolerance and oral
administration, are conditions highly desirable in leishmaniasis
treatment. Nevertheless, its action mechanism is still unknown and it
might be related to leishmanicide direct effect and/or
immunomodulatory action (XU et al., 1996; IANARO et al., 2000).
Several reports have shown rate cure of 60 to 80% using antimony
in patients with cutaneous lesions caused by L. (Viannia) braziliensis
in Latin America. In contrast, in Manaus only 42.5% of the patients
were cured with this drug similar to other results already published
(OLIVEIRA-NETO et al., 1997; ROMERO et al., 2001). These data
support the high variability in cure rate of this disease depending on
Leishmania spp., the clinical picture and the geographical region
(SARAVIA et al., 1989; ROMERO et al., 2001; SOTO & TOLEDO,
2007). Besides, drug resistance that would be a naturally acquired
condition in leishmania, has been partially associated with poor
response (GROGL et al., 1992).
Due to an impressive decrease of leishmaniasis cases at the time,
the study was closed prematurely with a small size with 49 patients,
different from the estimated 202 and just before the difference became
statistically significant between the treatments. This fact, together with
operational difficulties related to the follow-up and species definition,
hinder a better evaluation of the results and their correlation with clinical
and epidemiological factors, but evidenced a very low efficacy of
azithromycin to treat cutaneous leishmaniasis in Manaus.
RESUMO
Falha da azitromicina e do antimonial no tratamento da
leishmaniose cutânea em Manaus, AM, Brasil
Com o objetivo de avaliar a eficácia da azitromicina no tratamento
da leishmaniose cutânea, foi realizado ensaio comparativo, em Manaus.
Foram recrutados 49 pacientes de ambos os sexos, com idades entre
14 e 70 anos que apresentassem úlceras cutâneas com menos de três
meses de evolução e que tivessem exame direto positivo para
amastigotas de leishmânia. Estes pacientes foram alocados em dois
grupos assim: Grupo I (26) recebeu uma dose diária de 500 mg de
azitromicina pela via oral durante 20 dias e o Grupo II, recebeu uma
dose diária de 20 mg/kg de antimoniato de meglumina por via
intramuscular, durante 20 dias. Do grupo da azitromicina, três (12,5%)
de 24 pacientes curaram 60, 90 e 120 dias, respectivamente, enquanto,
em 21 (87,5%) de 24 houve falha terapêutica. No grupo do antimonial,
oito (42,5%) de 19 pacientes curaram como segue: três no dia 30, um
no dia 60, um no dia 90 e três no dia 120. Contudo, em 11 (57,9%) de
19 casos, houve falha terapêutica. A azitromicina foi menos eficaz do
que o antimonial, embora, a análise da taxa de resposta por intenção
de tratamento não mostrou diferença significativa, entre eles. A
azitromicina foi melhor tolerada; porém, mostrou-se pouco eficaz no
tratamento da leishmaniose cutânea, em Manaus.
ACKNOWLEDGEMENTS
The study was supported by CNPq and FUNASA. We are grateful
to the kind assistance of the staff at Fundação de Medicina Tropical do
Amazonas, Manaus, AM, and to Angela Azor and Maria Rita de Souza
for technical assistance.
REFERENCES
1. ALRAJHI, A.A.; IBRAHIM, E.A.; DE VOL, E.B. et al. - Fluconazole for the treatment
of cutaneous leishmaniasis caused by Leishmania major. New Engl. J. Med., 346:
891-895, 2002.
2. DAOUD, S. & BOUSHI, L. - Azithromycin ineffective in the treatment of old-world
cutaneous leishmaniasis. Int. J. Derm., 45: 1126-1128, 2006.
3. DOGRA, J. & SAXENA, V.N. - Itraconazole and leishmaniasis: a randomised double-
blind trial in cutaneous disease. Int. J. Parasit., 26: 1413-1415, 1996.
160
TEIXEIRA, A.C.; PAES, M.G.; GUERRA, J.O.; PRATA, A. & SILVA-VERGARA, M.L. - Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil.
Rev. Inst. Med. trop. S. Paulo, 50(3): 157-160, 2008.
4. GIACOMETTI, A.; CIRIONI, O.; BARCHIESI, F.; ANCARINI, F. & SCALISE, G. -
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin
against Cryptosporidium parvum in cell culture. J. Antimicrob. Chemother., 45:
453-456, 2000.
5. GRIMALDI Jr., G.; TESH, R.B. & McMATTON-PRATT, D. - A review of geographical
distribution and epidemiology of leishmaniasis in the New World. Amer. J. trop.
Med. Hyg., 41: 687-725, 1989.
6. GROGL, M.; THOMASON, T.N. & FRANKE, E.D. - Drug resistance in leishmaniasis:
its implications in systemic chemotherapy of cutaneous and mucocutaneous disease.
Amer. J. trop. Med. Hyg., 47: 117-126, 1992.
7. IANARO, A.; LALENTI, A.; MAFFIA, P. et al. - Antiinflammatory activity of macrolide
antibiotics. J. Pharmacol. exp. Ther., 292: 156-163, 2000.
8. KROLEWIECKI, A.J.; LEON, S.; SCOTT, P. & ABRAHAM, D. - Activity of azithromycin
against Leishmania major in vitro and in vivo. Amer. J. trop. Med. Hyg., 67: 273-
277, 2002.
9. LAINSON, R. & SHAW, J.J. - Evolution, classification and geographical distribution of
leishmania. In: PETERS, W. & KILLIK-KENDRICK, R., ed. The leishmaniasis in
biology and epidemiology. London, Academic Press, 1987. p. 1-120.
10. MAYRINK, W.; WILLIAMS, P.; COELHO, M.B. et al. - Epidemiology of dermal
leishmaniasis in the Rio Doce Valley, state of Minas Gerais, Brazil. Ann. trop. Med.
Parasit., 73: 123-137, 1979.
11. OLIVEIRA-NETO, M.P.; SCHUBACH, A.; MATTOS, M.; GONÇALVES-COSTA, S.C.
& PIRMEZ, C. - A low-dose antimony treatment in 159 patients with American
cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Amer. J. trop.
Med. Hyg., 57: 651-655, 1997.
12. PETERS, D.H.; FRIEDEL, H.A. & McTAVISH, D. - Azithromycin. A review of its
antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs, 44:
750-799, 1992.
13. PRATA, A.; SILVA-VERGARA, M.L.; COSTA, L. et al. - Efficacy of azithromycin in
the treatment of cutaneous leishmaniasis. Rev. Soc. bras. Med. trop., 36: 65-69,
2003.
14. PUKRITTAYAKAMEE, S.; CLEMENS, R.; CHANTRA, A. et al. - Therapeutic responses
to antibacterial drugs in vivax malaria. Trans. roy. Soc. trop. Med. Hyg., 95: 524-
528, 2003.
15. ROCHA, P.N.; ALMEIDA, R.P.; BACELLAR, O. et al. - Down-regulation of Th1 type
of response in early human American cutaneous leishmaniasis. J. infect. Dis., 180:
1731-1734, 1999.
16. ROMERO, G.A.S.; GUERRA, M.V.F.G.; PAES, M.G. & MACEDO, V.O. - Comparison
of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.)
guyanensis in Brazil: therapeutic response to meglumine antimoniate. Amer. J. trop.
Med. Hyg., 65: 456-465, 2001.
17. SARAVIA, N.G.; VALDERRAMA, L.; LABRADA, M. et al. - The relationship of
Leishmania braziliensis subspecies and immune response to disease expression in
New World leishmaniasis. J. infect. Dis., 159: 725-735, 1989.
18. SILVA-VERGARA, M.L.; SILVA, L.A.; MANEIRA, F.R.Z.; SILVA, A.G. & PRATA, A.
- Azithromycin in the treatment of mucosal leishmaniasis. Rev. Inst. Med. trop. S.
Paulo, 46: 175-177, 2004.
19. SOTO, J.; ARANA, B.A.; TOLEDO, J. et al. - Miltefosine for New World cutaneous
leishmaniasis. Clin. infect. Dis., 38:1266-1272, 2004.
20. SOTO, J.; TOLEDO, J.; GUTIERREZ, P. et al. - Treatment of American cutaneous
leishmaniasis with miltefosine, an oral agent. Clin. infect. Dis., 33: 57-61, 2001.
21. SOTO, J. & TOLEDO, J.T. - Oral miltefosine to treat new world cutaneous leishmaniasis.
Lancet infect. Dis., 7: 7, 2007.
22. SUNDAR, S.; JHA, T.K.; THAKUR, C.P. et al. - Oral miltefosine for Indian visceral
leishmaniasis. New. Engl. J. Med., 347: 1739-1746, 2002.
23. TEIXEIRA, A.C.; PAES, M.G.; GUERRA, J.O.; PRATA, A. & SILVA-VERGARA, M.L.
- Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM,
Brazil. Rev. Inst. Med. trop. S. Paulo, 49: 235-238, 2007.
24. VERA, L.A.; SANTOS, J.B.; MACÊDO, V.O. et al. - Avaliação da influência da infecção
bacteriana secundária na evolução da leishmaniose cutânea em Corte de Pedra, Bahia.
Rev. Soc. bras. Med. trop., 34: 233-237, 2001.
25. WILDFEUER, A.; LAUFEN, H. & ZIMMERMANN, T. - Uptake of azithromycin by
various cells and its intracellular activity under in vivo conditions. Antimicrob. Agents
Chemother., 40: 75-79, 1996.
26. XU, G.; FUJITA, J.; NEGAYAMA, K. et al. - Effect of macrolide antibiotics on
macrophage functions. Microbiol. Immunol., 40: 473-479, 1996.
Received: 26 September 2007
Accepted: 2 April 2008
